Viking Therapeutics Lands $547.8 Million War Chest as VK2735 Maintenance Data Wins Over Oppenheimer
Published on 10/01/2026 at 19:11 | Editorial boerse-global.de
Viking Therapeutics has pulled off a dual financing that hands the biotech a projected net proceeds figure of roughly $547.8 million — capital the company intends to funnel into its obesity and metabolic pipeline at a moment when its lead candidate is drawing fresh praise from Wall Street.
The raise combined common stock with convertible debt. Viking sold 9,035,714 shares at $35.00 apiece alongside 2.00% convertible notes due 2032 carrying an aggregate principal amount of $258.75 million. With the underwriting banks exercising their options in full, gross proceeds reached about $575.0 million.
Dilution Worries Weigh on the Share Price
Investors greeted the news with the familiar reflex that follows most equity issuances: concern over a diluted stake. The stock came under selling pressure once the plans surfaced, and the shares have since slipped 11% over a seven-day stretch. At €28.80, Viking carries a market capitalization of €3.62 billion.
The arithmetic behind that caution is straightforward — more shares in circulation shrink each existing holder's slice of the company. Yet the more consequential question is whether the cash now in hand gives Viking the staying power to compete against far larger rivals in the obesity treatment arena.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Management has earmarked the funds chiefly for advancing VK2735 and VK3019, two programs that require lengthy and expensive clinical trial work. Steering drug candidates through late-stage testing demands deep financial endurance, and the company has now removed the near-term risk of running dry.
Maintenance Data Hits the Industry's Weak Spot
The financing lands just weeks after Viking released a weight-loss study update for VK2735 that addressed one of the class's most stubborn problems. Patients dosed every two weeks retained up to 97% of their prior weight loss, while those on a monthly schedule kept as much as 90% over a 12-week period.
That durability matters because many patients on modern obesity drugs regain weight quickly after stopping treatment. A workable long-term strategy therefore shapes both the medical value and the commercial potential of any candidate — even the strongest initial results fade without a viable plan for sustained use.
Additional data reinforced the case. Continued weekly dosing of 17.5 mg produced a mean weight reduction of 21.7% from baseline after 33 weeks, with no plateau observed. The flexibility in dosing intervals could become a genuine competitive edge in later marketing, giving physicians and patients more room to maneuver in chronic use.
Oppenheimer Lifts Its Target to $120
Analyst Jay Olson at Oppenheimer raised his price target on the stock from $100 to $120 on September 22, according to media reports, keeping an Outperform rating. He pointed to the VK2735 maintenance data as the driver behind the upgrade.
Viking Therapeutics at a turning point? This analysis reveals what investors need to know now.
That endorsement stands in contrast to the recent tape. The shares now trade 30% below their 52-week high, a decline that captures how soberly market participants are re-pricing the balance between capital hunger and research risk.
For those tracking the sector, the tension is clear: the obesity market rewards clinical breakthroughs but reacts sharply to the cost of getting there. The recent pullback looks more like the typical pattern that follows large placements than a verdict on the pipeline itself. With a fortified balance sheet and compelling maintenance results in hand, Viking appears operationally sturdier than it was before the financing — though investors in this space need patience as much as faith in the science.
Ad
Viking Therapeutics Stock: New Analysis - 1 October
Fresh Viking Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
